In this episode, we explore how Trump's 'most favored nation' policy is pressuring pharmaceutical companies to lower US drug prices, creating a ripple effect across Europe. As companies attempt to offset losses by seeking higher prices in Europe, healthcare systems in the UK, Germany, and Denmark face difficult choices. We examine the impact on drug availability, the challenges for Europe's budget-constrained systems, and how countries are responding to protect their interests. With the UK caught in a delicate balancing act and European nations holding firm to their principles, we uncover the high-stakes game of global drug pricing negotiations.
Related Episodes
China's Economic Growth: Resilience Amidst Trade Tensions
China's economy expands 5.2% in Q2, outpacing forecasts. How is it managing growth amidst trade tensions and domestic challenges?
Revitalizing Australia's Capital Markets: Insights from Bain Capital's Mike Murphy
Discover how the Virgin Australia IPO sparked a wave of new listings and what it means for Australia's capital markets recovery.
Navigating Global Markets: ECB, Trump's Tariffs, and UK Inflation
Alice and Lewis discuss the ECB's stance on the euro, the impact of Trump's tariffs on US PMI, and the UK's inflation and growth challenges.
Wise's Shareholder Rebellion: A Corporate Governance Battle
A fintech giant faces a major shareholder rebellion as co-founder Taavet Hinrikus pushes back against governance changes tied to a US dual listing. Will the UK market lose its grip on tech listings?
UK and France Strengthen Nuclear Cooperation: A New Era for European Security
Discover how the UK and France are deepening their nuclear coordination in response to growing regional tensions and what this means for European security.
The Hidden Uranium: US Airstrikes and Iran's Nuclear Ambitions
New revelations suggest Iran's uranium stockpile remains intact after US airstrikes, challenging Trump's claims of complete destruction. What's the real impact of the attacks, and what does it mean for global security?
MHRA's New Strategy: Innovation and Global Collaboration Post-Brexit
How is the MHRA rebranding itself as a fast, innovative regulatory body in the life sciences sector? Learn about their 10-year NHS revitalization plan and global partnerships.
WH Smith Renegotiates Sale: High Street Uncertainty Looms
The high street faces more uncertainty as WH Smith renegotiates its sale to Modella Capital, with the price dropping from £52m to £40m.
The 2004 Immigration Memo: A Wake-Up Call for the Labour Government
Uncover the explosive 2004 memo warning Tony Blair about public backlash against immigration and asylum seekers.
The Rise of Post-Layoff Support Networks and Worker Resistance
In the wake of mass layoffs, workers are forming private online groups to support each other and resist corporate pressures. Today, we explore how these networks are reshaping the job market and worker solidarity.
UK Restaurant Sales: Weather-Driven Delivery Growth in May
Discover how May's weather boosted restaurant delivery sales by 1.8%, but overall sales still face challenges.
M&A Market Volatility: Geopolitical Tensions and Strategic Deals
Deal-making in the UK has hit a decade-low, but strategic megadeals are keeping transaction values steady. Alice and Lewis explore the impact of Trump's tariffs and global conflicts on M&A trends.